TACROLIMUS
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
LIVER TRANSPLANTATION
Conditions
LIVER TRANSPLANTATION
Trial Timeline
May 1, 2005 → Oct 1, 2007
NCT ID
NCT00321074About TACROLIMUS
TACROLIMUS is a phase 3 stage product being developed by Astellas Pharma for LIVER TRANSPLANTATION. The current trial status is completed. This product is registered under clinical trial identifier NCT00321074. Target conditions include LIVER TRANSPLANTATION.
What happened to similar drugs?
9 of 20 similar drugs in LIVER TRANSPLANTATION were approved
Approved (9) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189761 | Phase 2 | Completed |
| NCT00293930 | Phase 3 | Completed |
| NCT00189787 | Phase 2 | Completed |
| NCT00189722 | Phase 2 | Completed |
| NCT03465969 | Approved | Completed |
| NCT02555787 | Pre-clinical | Completed |
| NCT02147938 | Pre-clinical | Completed |
| NCT02143479 | Pre-clinical | Completed |
| NCT02159651 | Pre-clinical | Completed |
| NCT02057484 | Pre-clinical | Completed |
| NCT02377609 | Pre-clinical | Terminated |
| NCT01745159 | Approved | Completed |
| NCT01511003 | Approved | Completed |
| NCT01316133 | Approved | Terminated |
| NCT01410162 | Approved | Completed |
| NCT02963103 | Approved | Terminated |
| NCT01224041 | Approved | Completed |
| NCT01224418 | Approved | Completed |
| NCT00504348 | Phase 2/3 | Completed |
| NCT01410747 | Pre-clinical | Completed |
Competing Products
20 competing products in LIVER TRANSPLANTATION